Pulmonary Manifestations of Systemic Lupus Erythematosus Among Adults in Aseer Region, Saudi Arabia
Nouf Alhammadi,Hanan Alqahtani,Syed Mahmood,Abdulrahman Alshahrani,Abdullaziz Alahmari,Abdullah Alshahrani,Abdullah Badawi,Ali Alqahtani,Abdullah Alsalem,Mohammed Saeed Alqahtani,Mohammed Gazzan
DOI: https://doi.org/10.2147/ijgm.s449068
IF: 2.145
2024-03-15
International Journal of General Medicine
Abstract:Nouf A Alhammadi, 1, &ast Hanan Saeed Alqahtani, 2, &ast Syed Esam Mahmood, 3, &ast Abdulrahman Arif Alshahrani, 4, &ast Abdullaziz Motlaq A Alahmari, 4, &ast Abdullah Rashid Safer Alshahrani, 4, &ast Abdullah Saeed A Badawi, 4, &ast Ali Mohammed Ali Alqahtani, 4, &ast Abdullah Thabet A Alsalem, 4, &ast Mohammed Saeed M Alsultan Alqahtani, 4, &ast Mohammed Ali Gazzan 4, &ast 1 Department of Medicine, College of Medicine, King Khalid University, Abha, Saudi Arabia; 2 Department of Internal Medicine and Rheumatology, Aseer Central Hospital, Abha, Saudi Arabia; 3 Department of Family and Community Medicine, College of Medicine, King Khalid University, Abha, Saudi Arabia; 4 College of Medicine, King Khalid University, Abha, Saudi Arabia &astThese authors contributed equally to this work Correspondence: Syed Esam Mahmood, Department of Family and Community Medicine, College of Medicine, King Khalid University, Abha, 62529, Saudi Arabia, Email Background: Nearly half of the Systemic lupus erythematosus (SLE) patients develop lung involvement. The study assessed the extent of pulmonary involvement among SLE patients and to identify the associated factors in the population. Methodology: This retrospective cohort study was conducted at Aseer Hospital and Khamis Myshat Hospital in the Southern region of Saudi Arabia. The study spanned from January 1, 2016, to June 3, 2023. Patient inclusion criteria encompassed individuals who received a definitive diagnosis and classification as per American College of Rheumatology criteria, while patients under 18 years of age and those with mixed connective tissue diseases were exclude. Results: A total of 247 participants were included. 41.7% (n=103) aged 41 years and older, 95.1% (n = 235) were females. Around 10.10% had diabetes mellitus and 17.00% had hypertension and hypothyroidism. Lupus Nephritis was in 15.40%. Chest involvement was reported in 21.9%, in the form of pleuritis (6.10%), pleural effusion (4.00%), and lupus pneumonitis (4.00%), interstitial lung disease (4.00%), pulmonary embolism (3.60%) of individuals, and pulmonary hemorrhage (2.80%). The respiratory symptoms reported by SLE were; dyspnea, cough, and chest pain each having a prevalence of around 18.0%. Palpitations have a relatively high occurrence at 13.80%. Meanwhile, hemoptysis (blood coughing) has a lower prevalence of 1.20%, and fever is reported at 2.80%. Having chronic kidney disease and hypertension were significantly associated with having pulmonary involvement; (χ 2=3.308, p=0.027) and (χ 2=7.782, Fisher's p=0.002) respectively. The seropositivity for antiphospholipid Abs, anti-CCP, and antids-DNA were significantly associated with pulmonary involvement (χ 2=3.239, =p=0.049), (χ 2=4.621, Fisher's p=0.023), and (χ 2=8.248, p=0.010) respectively. Conclusion: The study found that 21.9% of SLE patients experience chest involvement, with varying degrees of pulmonary symptoms. Factors such as chronic kidney disease, hypertension, antiphospholipid antibodies, Anti-CCP positivity, and seropositivity for Anti-dsDNA were found to be significant associations with lung involvement, contributing to our understanding of SLE. Keywords: Systemic lupus erythematosus, pulmonary manifestation, Anti-dsDNA antibodies, ANA Systemic lupus erythematosus is a chronic autoimmune illness characterized by a variety of clinical and immunological abnormalities. 1 SLE-related complications can affect all compartments of the lungs and include pleuritis, interstitial lung disease (ILD), alveolar hemorrhage, shrinking lung syndrome (SLS), pulmonary hypertension (PH), airways disease, and thromboembolic disease. 2 Clinicians awareness of SLE-related pulmonary symptoms and the development of more sensitive techniques capturing lung involvement have led to the realization that subclinical lung involvement occurs more frequently than clinically discernible involvement. 3,4 Clinical evaluations of SLE patients should usually include a comprehensive examination for respiratory problems. 4,5 Some asymptomatic patients may present with incidental findings of abnormal chest imaging or lung function tests. 6 Serological indications such as elevated erythrocyte sedimentation rate (ESR), low complement, and increased double-stranded DNA (dsDNA) antibody titers, urge further need to evaluate whether the new respiratory symptoms are caused by lupus. 7,8 It has been reported that around 20 -Abstract Truncated-
medicine, general & internal